Kwak Eunice L, Clark Jeffrey W, Chabner Bruce
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA.
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5232-7. doi: 10.1158/1078-0432.CCR-07-1385.
The success of molecularly targeted agents (MTA) in the treatment of cancer has led to the investigation of their use in combination with other MTAs and with conventional chemotherapies. An overview of the MTAs that have emerged as Food and Drug Administration-approved drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic effect.
分子靶向药物（MTA）在癌症治疗中的成功促使人们研究其与其他MTA以及传统化疗联合使用的情况。本文概述了已获美国食品药品监督管理局批准的MTA，并提供了一个框架，以考虑如何最佳地联合使用MTA以最大化治疗效果。
